CN103599343A - Pharmaceutical composition for treating diabetes, and preparation method and application thereof - Google Patents
Pharmaceutical composition for treating diabetes, and preparation method and application thereof Download PDFInfo
- Publication number
- CN103599343A CN103599343A CN201310630084.2A CN201310630084A CN103599343A CN 103599343 A CN103599343 A CN 103599343A CN 201310630084 A CN201310630084 A CN 201310630084A CN 103599343 A CN103599343 A CN 103599343A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical composition
- preparation
- rhizoma coptidis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A provided pharmaceutical composition for treating diabetes is a preparation prepared from the following bulk drugs in parts by weight: 10-60 parts of coptis, 10-60 parts of radix asparagi, 10-60 parts of rehmannia glutinosa, 10-60 parts of dark plum, 5-20 parts of ginseng and 2-12 parts of cinnamomum cassia. The invention also provides a preparation method and application of the pharmaceutical composition. Tests show that: the pharmaceutical composition is precise and appropriate in compatability, is capable of effectively reducing blood sugar, is substantially more excellent in drug effect activity than classic prescription Lianmeitang and Jiaotai pill, and helps to provide a new choice for clinical medication for treating diabetes.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of diabetes and its production and use.
Background technology
Diabetes are to act on that body causes hypoinsulinism, insulin resistant etc. and a series of metabolism disorder syndromes such as the sugar that causes, protein, fat, power and water Xie Zhi by various virulence factors such as inherited genetic factors, immunologic function disorder, infected by microbes and toxin thereof, free radical toxin, Nervous and Mental Factors, and its pathomechanism is mainly defect of insulin secretion or insulin action defect.Main feature is that blood glucose is too high, glycosuria, polyuria, polydipsia, polyphagia, become thin, tired.Diabetes are mainly divided into four large classes, i.e. type 1 diabetes, type 2 diabetes mellitus, other specific type diabetes and gestational diabetes.In recent years, diabetes have become the third-largest disease of serious harm human health after tumor, cardiovascular and cerebrovascular disease.Whole world diabetics number cumulative year after year.Within 2008, China's diabetics has 4,300 ten thousand, increases every year by approximately 1,200,000 people, increases by approximately 3000 people every day, becomes global diabetics number the first big country.Wherein, type 2 diabetes mellitus has accounted for approximately 95% in diabetics.Therefore, strengthen the dynamics prevent and treat diabetes, particularly type 2 diabetes mellitus and become the task of top priority.
At present, Drug therapy type 2 diabetes mellitus is main mainly with Western medicine.Mainly contain following a few class hypoglycemic medicine, as insulin secretion stimulators, it represents that medicine is glimepiride, glibenclamide (yellow ureide derivative medicine); Biguanides, represents that medicine is metformin; Euglycemic agent, represents that medicine has troglitazone, rosiglitazone and pioglitazone (thiazolidinediones); Small intestinal alpha-glucosidase inhibitor, represents that medicine has acarbose (acarbose); Aldose reductase inhibitor, represents that medicine has tolrestat and epalrestat; Non-yellow ureide derivative Insulin-secreting agent, represents that medicine is repaglinide, Nateglinide, etc.Western medicine type 2 diabetes mellitus, has advantages of effective control post-prandial glycemia, but long-term taking easily produces toleration, also can bring larger side effect to health.
Chinese medicine has certain advantage in treatment diabetes: toxic and side effects is little, is suitable for long-term taking; Medicine source is wide, is difficult for producing toleration.In recent years, the domestic single medicinal material of having found to have hypoglycemic activity has just surpassed 60 kinds, a plurality of blood sugar lowering Chinese patent medicines have also in succession been developed, for example, patent of invention 200710300014.5, denomination of invention: the Chinese patent medicine and the production technology thereof that are used for the treatment of diabetes, this patent discloses a kind of Chinese patent medicine for the treatment of diabetes, it contains following raw material: Radix Ophiopogonis, Radix Asparagi, Radix Scrophulariae, Rhizoma Coptidis, Rhizoma Alismatis, Poria, Cortex Lycii, the Radix Astragali, Fructus Corni, Fructus Lycii, Radix Rehmanniae, Radix Rehmanniae Preparata, Radix Trichosanthis, Radix Ginseng, Cornu Cervi Pantotrichum, Bombyx Batryticatus, the sensitivity of its energy enhancing body to insulin, reduce blood glucose, blood fat and conditioning internal organs, nourishing the liver and kidney.Number of patent application: 97100874.4, denomination of invention: the formula of kebixiao pill, kebixiao plaster and production method, a kind of medicine for the treatment of of the inside combined with the outside treatment diabetes is also provided in this application, wherein, the prescription of medicine for external use comprises the 20 multi-flavor medical materials such as raw Carapax Trionycis, Fructus Schisandrae Chinensis, Cortex Lycii, Radix Rehmanniae Preparata, Radix Rehmanniae, Radix Asparagi, Radix Ophiopogonis, Fructus Mume, Radix Polygoni Multiflori, Radix Codonopsis, Rhizoma Coptidis, Radix Scrophulariae, the Radix Astragali, Poria, the Rhizoma Anemarrhenae, Rhizoma Alismatis, Radix Sophorae Flavescentis, Radix Puerariae, Rhizoma Dioscoreae, Herba Spirodelae grass, mussel powder, Pancreas Sus domestica gland.Lu Xiong etc. study discovery, hand over safe ball (Rhizoma Coptidis: Cortex Cinnamomi=1:1) Rat Model of Type 2 Diabetes of high glucose and high fat forage feed associating low dosage streptozotocin injection is had the effect of blood sugar lowering and serum triglycerides, but body weight, insulin level are not made significant difference, its mechanism may with improve the relevant (Lu Xiong of insulin sensitivity, Deng, hand over the experimentation of safe ball blood sugar reducing function, Liaoning Journal of Traditional Chinese Medicine, 34 9 phases of volume in 2007).
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of diabetes and its production and use.
The invention provides a kind of pharmaceutical composition for the treatment of diabetes, it is the preparation being prepared from by the crude drug that comprises following weight proportion:
Rhizoma Coptidis 10-60 part, Radix Asparagi 10-60 part, Radix Rehmanniae 10-60 part, Fructus Mume 10-60 part, Radix Ginseng 5-20 part, Cortex Cinnamomi 2-12 part.
Further, it is the preparation being prepared from by the crude drug that comprises following weight proportion:
30 parts of Rhizoma Coptidis, 6 parts of Cortex Cinnamomis, 15 parts of Radix Ginsengs, 30 parts of Radix Asparagis, 30 parts of Radix Rehmanniae, 30 parts of Fructus Mumes.
Further, it is the preparation that the crude drug by following weight proportion is prepared from:
Rhizoma Coptidis 25-35 part, Cortex Cinnamomi 4-8 part, Radix Ginseng 12-18 part, Radix Asparagi 25-35 part, Radix Rehmanniae 25-35 part, Fructus Mume 25-35 part.
Preferably, it is the preparation that the crude drug by following weight proportion is prepared from:
30 parts of Rhizoma Coptidis, 6 parts of Cortex Cinnamomis, 15 parts of Radix Ginsengs, 30 parts of Radix Asparagis, 30 parts of Radix Rehmanniae, 30 parts of Fructus Mumes.
Further, described Radix Rehmanniae is selected from Radix Rehmanniae.
In this pharmaceutical composition, Rhizoma Coptidis, bitter cold blood sugar lowering, is monarch drug; Fructus Mume, sour in the mouth, blood sugar lowering promotes the production of body fluid; The Radix Rehmanniae, clearing away heat and cooling blood YIN nourishing and the production of body fluid promoting; Radix Asparagi, YIN nourishing and the production of body fluid promoting; Be ministerial drug altogether; Radix Ginseng, protection islet cells, strongly invigorating primordial QI; Cortex Cinnamomi, warming and recuperating the gate of life, the nature and flavor of restriction Rhizoma Coptidis bitter cold; Share with Rhizoma Coptidis, restoring normal coordination between the heart and kidney, is adjuvant drug altogether.After above-mentioned each medicine compatibility, brought into play synergism, drug action significantly strengthens.
The present invention also provides said medicine preparing hypoglycemic medicine or/and the purposes in health product.
Further, described medicine is or/and health product are that treatment or the medicine of prevent diabetes are or/and health product.
Further, described diabetes are type 2 diabetes mellitus.
The present invention tests and shows, pharmaceutical composition compatibility of the present invention is precise and appropriate, can effectively reduce blood glucose, and its drug activity is significantly better than classical side Lian Meitang and Jiao Tai ball, for treating the clinical application of diabetes, provides new selection.
The specific embodiment
The preparation of embodiment 1 pharmaceutical composition of the present invention
Get Rhizoma Coptidis 30g, Cortex Cinnamomi 6g, Radix Ginseng 15g, Radix Asparagi 30g, Radix Rehmanniae 30g, Fructus Mume 30g; Add 8 times of water gagings to decoct 3 times, each 0.5h, merges decocting liquid, filters, and after filtrate is concentrated, adds suitable soluble starch, granulates.
The preparation of embodiment 2 pharmaceutical compositions of the present invention
Get Rhizoma Coptidis 30g, Cortex Cinnamomi 6g, Radix Ginseng 15g, Radix Asparagi 30g, Radix Rehmanniae 30g, Fructus Mume 30g; Add 8 times of water gagings to decoct 3 times, each 0.5h, merges decocting liquid, filters, and after filtrate is concentrated, dry, adds appropriate microcrystalline Cellulose, mixes, encapsulated.
The preparation of embodiment 3 pharmaceutical compositions of the present invention
Get Rhizoma Coptidis 35g, Cortex Cinnamomi 4g, Radix Ginseng 12g, Radix Asparagi 25g, Radix Rehmanniae 25g, Fructus Mume 25g, add 80%v/v alcohol reflux 2 times, alcohol extract is standby; Medicinal residues add 8 times of water gagings to decoct 2 times, merge decocting liquid; Alcohol extract reclaims after ethanol, merges with decocting liquid, after concentrating, adds suitable soluble starch, granulates, and obtains granule.
The preparation of embodiment 4 pharmaceutical compositions of the present invention
Get Rhizoma Coptidis 25g, Cortex Cinnamomi 8g, Radix Ginseng 18g, Radix Asparagi 35g, Radix Rehmanniae 35g, Fructus Mume 35g, beat powder, sieve, add appropriate microcrystalline Cellulose, mix, the encapsulated capsule that obtains.
By test example, illustrate beneficial effect of the present invention below.
The therapeutical effect of test example 1 diabetes
1, trial drug
Rhizoma Coptidis group: get Rhizoma Coptidis single medical material appropriate
Fructus Mume group: get Fructus Mume single medical material appropriate
Hand over safe ball group: Rhizoma Coptidis: Cortex Cinnamomi=30:30
Lian Meitang group: Coptis Teeta Wall: Fructus Mume: Radix Ophiopogonis: the Radix Rehmanniae: Colla Corii Asini=30:45:45:45:30
Rhizoma Coptidis+Fructus Mume group: Rhizoma Coptidis: Fructus Mume=30:30
The Radix Rehmanniae+Radix Asparagi+Rhizoma Coptidis+Fructus Mume group, the Radix Rehmanniae: Radix Asparagi: Rhizoma Coptidis: Fructus Mume=30:30:30:30
The Radix Rehmanniae+Radix Asparagi+Rhizoma Coptidis+Fructus Mume+Radix Ginseng+Cortex Cinnamomi group, the Radix Rehmanniae: Radix Asparagi: Rhizoma Coptidis: Fructus Mume=30:30:30:30:15:6
The above-mentioned medical material of respectively organizing, adds respectively 8 times of decoctings and boils 3 times, merges decocting liquid, after appropriate concentrating, standby, is trial drug.
2, test method
Experiment divides 8 groups, and every group of 12 Wistar rats adopt lumbar injection STZ55mg/Kg modeling.Except model group, all treatment rat equal Chinese medicine gavages 8 weeks (W), each Chinese drug-treated group dosage is this dosage of 20mg/Kg(and calculates with crude drug in whole).Detect fasting glucose (FPG) and 2h-plasma glucose (2hPG).
3, result of the test
See table.
Table 1
Statistic software SPSS 16.0, statistical method: single factor variance comparison.Statistical result:
Rhizoma Coptidis+Fructus Mume group and Rhizoma Coptidis group compare, P<0.05;
Rhizoma Coptidis+Fructus Mume group and the comparison of Fructus Mume group, P<0.01;
Rhizoma Coptidis+Fructus Mume group and Lian Meitang group compare, P>0.05;
The Radix Rehmanniae+Radix Asparagi+Rhizoma Coptidis+Fructus Mume group and Rhizoma Coptidis group compare, P<0.01;
The Radix Rehmanniae+Radix Asparagi+Rhizoma Coptidis+Fructus Mume group and the comparison of Fructus Mume group, P<0.01;
The Radix Rehmanniae+Radix Asparagi+Rhizoma Coptidis+Fructus Mume group and Lian Meitang comparison, P<0.05;
The Radix Rehmanniae+Radix Asparagi+Rhizoma Coptidis+Fructus Mume group and the comparison of the safe ball group of friendship, P>0.05;
The Radix Rehmanniae+Radix Asparagi+Rhizoma Coptidis+Fructus Mume+Radix Ginseng+Cortex Cinnamomi group compares with Lian Meitang group, P<0.05;
The Radix Rehmanniae+Radix Asparagi+Rhizoma Coptidis+Fructus Mume+Radix Ginseng+Cortex Cinnamomi group and the comparison of the safe ball group of friendship, P<0.05;
The Radix Rehmanniae+Radix Asparagi+Rhizoma Coptidis+Fructus Mume+Radix Ginseng+Cortex Cinnamomi group compares with Rhizoma Coptidis group, P<0.01;
The Radix Rehmanniae+Radix Asparagi+Rhizoma Coptidis+Fructus Mume+Radix Ginseng+Cortex Cinnamomi group and the comparison of Fructus Mume group, P<0.01;
Model group and each group be P<0.01 relatively.
From the above results:
(1) after Rhizoma Coptidis being combined to use with Fructus Mume in the present invention, its blood sugar reducing function is obviously better than Rhizoma Coptidis, Fructus Mume is alone, shows to have brought into play synergistic function after both compatibilities; , compare with classics side Lian Meitang, Rhizoma Coptidis Fructus Mume group of the present invention has obviously been reduced flavour of a drug, and has changed the compatibility consumption of Rhizoma Coptidis and Fructus Mume meanwhile, and its drug activity and Lian Meitang are suitable.
(2) after the present invention uses Rhizoma Coptidis, Fructus Mume and the Radix Rehmanniae, Radix Asparagi compatibility, its blood sugar reducing function is obviously better than single medicine, shows that above-mentioned compatibility brought into play synergistic function; , compare with classics side Lian Meitang, its 2h-plasma glucose value is lower meanwhile, and between group, relatively has statistical significance (p<0.05), illustrates that present composition drug action is stronger.
(3) after the present invention uses Rhizoma Coptidis, Fructus Mume and the Radix Rehmanniae, Radix Asparagi, Radix Ginseng, Cortex Cinnamomi compatibility, its blood sugar reducing function is obviously better than classical side Lian Meitang and Jiao Tai ball, shows, after said medicine compatibility, to have brought into play synergism, and drug action significantly strengthens.
The present invention tests and shows, pharmaceutical composition compatibility of the present invention is precise and appropriate, can effectively reduce blood glucose, and its drug activity is significantly better than classical side Lian Meitang and Jiao Tai ball, for treating the clinical application of diabetes, provides new selection.
Claims (10)
1. a pharmaceutical composition for the treatment of diabetes, is characterized in that: it is the preparation being prepared from by the crude drug that comprises following weight proportion:
Rhizoma Coptidis 10-60 part, Radix Asparagi 10-60 part, Radix Rehmanniae 10-60 part, Fructus Mume 10-60 part, Radix Ginseng 5-20 part, Cortex Cinnamomi 2-12 part.
2. pharmaceutical composition according to claim 1, is characterized in that: it is the preparation being prepared from by the crude drug that comprises following weight proportion:
30 parts of Rhizoma Coptidis, 6 parts of Cortex Cinnamomis, 15 parts of Radix Ginsengs, 30 parts of Radix Asparagis, 30 parts of Radix Rehmanniae, 30 parts of Fructus Mumes.
3. pharmaceutical composition according to claim 1, is characterized in that: it is the preparation that the crude drug by following weight proportion is prepared from:
Rhizoma Coptidis 25-35 part, Cortex Cinnamomi 4-8 part, Radix Ginseng 12-18 part, Radix Asparagi 25-35 part, Radix Rehmanniae 25-35 part, Fructus Mume 25-35 part.
4. pharmaceutical composition according to claim 3, is characterized in that: it is the preparation that the crude drug by following weight proportion is prepared from:
30 parts of Rhizoma Coptidis, 6 parts of Cortex Cinnamomis, 15 parts of Radix Ginsengs, 30 parts of Radix Asparagis, 30 parts of Radix Rehmanniae, 30 parts of Fructus Mumes.
5. according to the pharmaceutical composition described in claim 1-4 any one, it is characterized in that: described Radix Rehmanniae is selected from Radix Rehmanniae.
6. according to the pharmaceutical composition described in claim 1-5 any one, it is characterized in that: described preparation is oral formulations.
7. the preparation method of pharmaceutical composition described in claim 1-6 any one, is characterized in that: it comprises following operating procedure:
(1) take by weight ratio each crude drug;
(2) each crude drug directly pulverized or added water or/and after ethanol extraction, add adjuvant conventional in pharmacy or health product or complementary composition, being prepared into conventional preparation.
8. the pharmaceutical composition described in claim 1-6 any one is being prepared hypoglycemic medicine or/and the purposes in health product.
9. purposes according to claim 8, is characterized in that: described medicine is or/and health product are that the medicine for the treatment of or prevent diabetes is or/and health product.
10. purposes according to claim 9, is characterized in that: described diabetes are type 2 diabetes mellitus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310630084.2A CN103599343B (en) | 2013-11-28 | 2013-11-28 | A kind of pharmaceutical composition for the treatment of diabetes and its production and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310630084.2A CN103599343B (en) | 2013-11-28 | 2013-11-28 | A kind of pharmaceutical composition for the treatment of diabetes and its production and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103599343A true CN103599343A (en) | 2014-02-26 |
| CN103599343B CN103599343B (en) | 2015-10-21 |
Family
ID=50117649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310630084.2A Expired - Fee Related CN103599343B (en) | 2013-11-28 | 2013-11-28 | A kind of pharmaceutical composition for the treatment of diabetes and its production and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103599343B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106214787A (en) * | 2016-09-20 | 2016-12-14 | 中国中医科学院西苑医院 | A kind of Chinese medicine composition treating diabetes and preparation method thereof and purposes |
| CN106421342A (en) * | 2016-10-20 | 2017-02-22 | 湖北三峡神农生物科技有限公司 | Pill composition with rhizoma anemarrhenae and coptis chinensis as well as effect of reducing blood sugar or blood lipid and detection method thereof |
| CN114712454A (en) * | 2022-03-11 | 2022-07-08 | 广州中医药大学科技产业园有限公司 | Application of pharmaceutical composition in preparation of medicines for treating cardiovascular diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856458A (en) * | 2010-06-10 | 2010-10-13 | 成都市翻鑫家科技有限公司 | Chinese medicament for treating diabetes mellitus |
| CN102441064A (en) * | 2011-12-27 | 2012-05-09 | 西南大学 | Traditional Chinese medicine composition for treating diabetes and preparation thereof |
-
2013
- 2013-11-28 CN CN201310630084.2A patent/CN103599343B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856458A (en) * | 2010-06-10 | 2010-10-13 | 成都市翻鑫家科技有限公司 | Chinese medicament for treating diabetes mellitus |
| CN102441064A (en) * | 2011-12-27 | 2012-05-09 | 西南大学 | Traditional Chinese medicine composition for treating diabetes and preparation thereof |
Non-Patent Citations (2)
| Title |
|---|
| 仝小林: "黄连为主药系列经方在糖尿病辩证中的运用", 《中医杂志》 * |
| 张龙等: "养阴法在消渴病各阶段治疗中的应用", 《辽宁中医药大学学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106214787A (en) * | 2016-09-20 | 2016-12-14 | 中国中医科学院西苑医院 | A kind of Chinese medicine composition treating diabetes and preparation method thereof and purposes |
| CN106421342A (en) * | 2016-10-20 | 2017-02-22 | 湖北三峡神农生物科技有限公司 | Pill composition with rhizoma anemarrhenae and coptis chinensis as well as effect of reducing blood sugar or blood lipid and detection method thereof |
| CN114712454A (en) * | 2022-03-11 | 2022-07-08 | 广州中医药大学科技产业园有限公司 | Application of pharmaceutical composition in preparation of medicines for treating cardiovascular diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103599343B (en) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103083531B (en) | Drug for treating diabetes | |
| CN100353983C (en) | Chinese medicine preparation for reducing sugar | |
| CN102225149B (en) | Traditional Chinese medicine compound for treating diabetes and preparation method thereof | |
| CN103566350A (en) | Pharmaceutical composition having blood sugar reducing effect | |
| CN103599215A (en) | Blood sugar-reducing medicament | |
| CN107495367A (en) | A kind of food, health products or pharmaceutical composition for improving hypoxia-bearing capability and its production and use | |
| CN102397372A (en) | Pharmaceutical composition, preparation and application of pharmaceutical composition in treating irritable bowel syndrome | |
| CN103599343B (en) | A kind of pharmaceutical composition for the treatment of diabetes and its production and use | |
| CN103223104B (en) | A kind of Chinese medicine composition treating diabetes and preparation method thereof | |
| CN103845607A (en) | Compound traditional Chinese medicinal preparation for preventing and treating diabetes mellitus and preparation method thereof | |
| CN103705578B (en) | There is blood fat reducing and Chinese medicine preparation suppressing blood glucose rising effect and preparation method thereof | |
| CN102961584A (en) | Traditional Chinese medicine composition capable of relieving fatigue, as well as preparation method and application thereof | |
| CN103566349B (en) | A kind of pharmaceutical composition for the treatment of hyperglycemia hyperlipidemia | |
| CN103585435A (en) | Pharmaceutical composition for treating diabetes | |
| CN101850071A (en) | Chinese medicament for treating chronic nephritis | |
| CN102205031B (en) | Traditional Chinese medicine for treating male sterility | |
| CN106563076B (en) | Medicine for treating stomach disease and its preparing method | |
| CN1194733C (en) | Medicine for treating hyperthyroidism and its prepn | |
| CN103550290B (en) | Chinese medicinal composition for treating type 2 diabetes | |
| CN114259540B (en) | Traditional Chinese medicine composition for treating diabetes with syndrome of deficiency of both qi and yin and preparation method and application thereof | |
| CN103191171A (en) | Natural medicine for treating 2 type diabetes, and preparation method thereof | |
| CN102836315A (en) | Chinese medicinal composition for preventing and conditioning prognosis tumors and preparation method thereof | |
| CN110420265B (en) | A Chinese medicinal composition for treating diabetes, and its preparation method | |
| CN101637573B (en) | Medicinal composition for treating diabetes and preparation method thereof | |
| CN101264208A (en) | Medicinal composition for treating stomach and intestine dysfunction and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151021 Termination date: 20201128 |